Objective. To determine the frequency of immunodeficiency-like states in SLE and related clinical features.
Introduction
SLE is associated with several types of primary immunodeficiency (PID) [1] . Deficiency of early components of the complement cascade (C1q, C2 and C4) are the most commonly reported forms of PID in SLE [2, 3] . Selective IgA deficiency (SIgAD) is the most common form of PID in the general population (1:4001:3000) [1, 4, 5] , and it is much more prevalent among SLE patients (5.2% in juvenile and 2.6% in adult SLE patients) [6] . Conversely, SLE affects 15% of SIgAD patients, which means up to 50-fold increased frequency compared with the normal population [7] . Chronic granulomatous disease (CGD) has a 2.7% frequency of discoid lupus and 0.5% of SLE [8] . Around 25% of common variable immunodeficiency patients develop some form of autoimmune manifestation, including SLE [911] . SLE has been associated with other forms of PID, such as IgG deficiency [12] , IgG 2 deficiency [13] , autosomal recessive hyper-IgE syndrome [14] , activation induced by deaminase-cytidine [15] or uracil-N-glycosylase deficiency [16] , CD40 and CD40L deficiency [17] , autoimmune lymphoproliferative syndrome [18, 19] and prolidase deficiency [20] .
The observation that dissimilar forms of PID are associated with SLE suggests that an immunodeficiency state per se might be involved in SLE pathophysiology. Several studies have addressed the occurrence of individual forms of PID in SLE, but no comprehensive survey on the occurrence of overall immunodeficiency in association with adult SLE has been published. Our group has recently reported that a sizable fraction of juvenile SLE (jSLE) patients presented one of several forms of PID [21] . Here, we present a cross-sectional study to determine the fraction of adult SLE patients presenting evidence of immunodeficiency compatible with a comprehensive array of PID forms. We hypothesize that SLE patients with some form of immunodeficiency-like state constitute a substantial subgroup of the SLE totality. In addition, we investigate whether this subgroup of patients presents distinct clinical, therapeutic or prognostic characteristics.
Methods
Three hundred and fifteen patients meeting the ACR criteria for SLE [22] were consecutively recruited at the Rheumatic Diseases Division, Universidade Federal de Sã o Paulo. The control group comprised 301 randomly selected healthy blood donors, sex-matched to the SLE group, with no evidence of autoimmune disease according to a structured medical interview. Patients and controls were at least 18 years old and signed an informed consent form. The study was approved by the Universidade Federal de Sã o Paulo Ethics Committee (CEP#0330/09). Exclusion criteria were the following: any infection within 30 days of study admission; use of immunobiological medication within the last 12 months; and malignant diseases. Patients were scored for cumulative SLE clinical manifestations, recurrent infections, current and previous medications, age at SLE onset, presence of other autoimmune diseases and determination of SLICC-DI [23] . These parameters were scored at the time the immunological parameters were defined, that is, at the first blood draw in cases with normal results, or at the second blood draw in cases in which a second blood draw was necessary for confirmatory definition (see below and Supplementary Fig. S1 , available at Rheumatology Online).
Patients and controls were investigated for immunological parameters relevant to immune competence evaluation. Controls and patients with inactive disease (SLEDAI = 0; [24] ) who exhibited abnormal immune competence (see below) were submitted to another blood draw after 60 days for confirmation of test results. Patients with any evidence of active SLE (SLEDAI 5 1) and abnormal test results were followed up to the end of the SLE flare and only then were submitted to retesting. Patients were classified as having an immunodeficiencylike state when immunological abnormalities were observed in two separate blood draws and SLE was inactive (SLEDAI = 0) at least in the second occasion. Patients persisting with active SLE throughout the study period were excluded ( Supplementary Fig. S1 , available at Rheumatology Online). Patients with residual proteinuria stable for >1 year (and no other manifestation of disease activity) were not considered as active SLE. According to this strategy, 15 out of 132 active SLE patients were excluded due to persistent disease activity ( Table 1) . The definition of immunodeficiency-like state followed the 2009 classification criteria for PID [25] . As a conservative precaution, for all the immunological parameters described below, we always considered the normal or higher values, when the patient was submitted to retesting.
Serum level of immunoglobulin isotypes, IgG subclasses and isohaemagglutinins was determined by immunoturbidimetry, ELISA or erythrocyte agglutination (Supplementary Table S1 , available at Rheumatology Online). Due to a possible influence of immunosuppressant therapy on immunoglobulin synthesis, we adopted a more stringent criterion for the classification of reduced immunoglobulin serum levels (3 standard deviations below mean levels for adults, as established in the literature; see Table 2 ) [26] . Immunoglobulin isotype serum levels above the reference range, established according to the manufacturers, were considered increased immunoglobulin serum levels.
Phagocyte oxidative burst was quantified by oxidation of 2,7-dichlorofluorescein diacetate at baseline and after stimulus with inactivated Staphylococcus aureus as reported [27] . Phagocytes were separated into monocytes and neutrophils according to CD14 labelling using FACSCalibur. Oxidative burst was estimated by the mean of fluorescence intensity [27] . CGD was defined as oxidative burst lower than 5%, and CGD gene carrier as oxidative burst between 5 and 70% of healthy controls and a bimodal pattern histogram.
Total haemolytic complement (CH50) and C2 were determined by immunohaemolytic assay [28] , C3 and C4 by immunoturbidimetry and C1q by radial immunodiffusion (Supplementary Table S1 , available at Rheumatology Online). Presumptive complement deficiency was defined as consistently reduced levels (according to the manufacturer) of one specific component associated with normal levels of all other components.
A normal CH50 result excluded classic pathway complement component deficiency. Subjects with consistently low or absent C2 levels underwent C2 genotyping for detection of type I C2 deficiency (Supplementary Table S2 , available at Rheumatology Online) [21] . Samples without type I C2 deficiency and those with persistently low C3 serum levels underwent gene sequencing.
C4A and C4B gene copy number (GCN) was determined by quantitative real time PCR and normalized by RNase P gene, as reported [29] . Experiments were run in triplicate in a Rotor-Gene 3000 PCR cycler under the conditions specified in Supplementary Table S2, available at Rheumatology Online. C4A and C4B GCN was determined using the normalized target gene expression level method [or DeltaDelta-C T (ÁÁC T ) method] where the GCN in the test sample is equal to the GCN in the control sample Â2 ÀðÁÁCTÞ , the ÁÁC T is equal to the control ÁC T minus the test sample ÁC T and the ÁC T in each sample is equal to RNase P C T (threshold cycle) minus C4A C T or C4B C T [29] . Reference samples with known C4A and C4B GCN were kindly provided by Dr Agnes Szilagyi, Semmelweis University, Budapest, Hungary. Low C4 GCN was defined as less than two copies of total C4 (C4A plus C4B GCN). C4 deficiency-like state was defined as low total C4 GCN or absence of one gene (C4A or C4B) plus persistently low C4 protein serum levels.
Variables with normal distribution (SmirnoffKolmogorov test) were analysed with Student's t test and those with non-parametric distribution with the MannWhitney test. Qualitative parameters were analysed by the chi-square test and Fisher's exact test when appropriate. Multiparametric analyses were performed with one-way analysis of variance (ANOVA) and post-ANOVA test (Bonferroni) when appropriate. Statistical inference level was set at 0.05.
Results
Clinical characteristics of patients are shown in Table 1 . Control subjects and patients did not differ with regard The sum of individual diseases results in a higher value than the overall total because some patients presented more than one disease simultaneously. b Non-autoimmune diseases: arterial hypertension, dyslipidaemia, OA, etc. The sum results in a higher value than the overall total because some patients used more than one medication simultaneously. d Antimalarials were not considered immunosuppressant. NRAID: non-rheumatic autoimmune diseases. Fig. S1 , available at Rheumatology Online).
There was a significantly higher frequency of individuals with overall immunodeficiency-like states in the SLE group (86; 28.7%) compared with controls (10; 3.3%; P < 0.001) ( Table 2 ). Low immunoglobulin serum levels was the predominant immunodeficiency-like state among patients and controls. However, the SLE group had a significantly higher frequency of individuals with IgM, IgG 2 , IgG 3 and IgG 4 serum levels below the normal range compared with controls ( Table 2 and Fig. 1 ). There was a threefold higher frequency of IgA deficiency in patients (1% vs 0.3%). Eighteen patients presented abnormally low serum levels of more than one IgG subclass (two patients with IgG 1 / IgG 2 /IgG 3 , six with IgG 2 /IgG 3 , and 10 with IgG 3 /IgG 4 deficiency-like state). These 18 patients were counted only once in the total number of patients with IgG subclass deficiency-like state. Despite the notable frequency of patients with IgG subclass deficiency-like state, the SLE group presented significantly higher median IgG 1 and IgG 3 than controls (P < 0.001; Fig. 1E and G) . Median IgA and IgG serum levels were also significantly higher in SLE compared with controls (P < 0.001; Fig. 1A and B). Overall, there was a significantly higher frequency of patients with serum levels of at least one immunoglobulin class above the normal range (135; 45%) compared with controls (31; 10.3%; P < 0.001).
Rigorous testing confirmed only two cases of complement deficiency-like state of any kind in SLE patients (both were C2 deficiency carriers). Initial testing did show 31 (10.3%) patients and six (2%) controls with potential abnormalities in CH50, C2 or C3. Upon retesting, however, abnormal results persisted in only 12 (4%) patients (nine C2, one C3 and two CH50) and one control (C2). These 13 individuals were genotyped; none presented type I C2 deficiency. The unique case of possible C3 deficiency and the 10 possible cases of C2 deficiency underwent gene sequencing (Supplementary Table S3 , available at Rheumatology Online). Two patients presented heterozygous disease-causing mutations in C2 gene and were considered C2 deficiency carriers. The patient with possible C3 deficiency showed irrelevant mutations. For the two patients with persistently isolated low CH50, C1q to C9 serum levels were measured. One patient presented isolated decrease in C6 serum levels (6.7 mg/dl; reference range 1228 mg/dl) and the other one had no abnormality. These two patients each had two copies of total C4, one with two copies of C4A and no C4B and the other with one copy each of C4A and C4B, and thus were not considered as having an immunodeficiency-like state.
The range of total C4 GCN varied from 2 to 7 in controls and 2 to 8 in SLE patients. C4A GCN varied from 0 to 6 in both groups and C4B GCN varied from 0 to 5 in controls and from 0 to 4 in SLE patients. Table 2 ). This female patient presented discoid lesions, photosensitivity, arthritis, oral ulcers, pericarditis, thrombocytopenia, GN, nuclear fine speckled pattern antinuclear antibody test at 1/ 1280 titre and anti-Sm and anti-double stranded DNA antibodies.
We investigated the medications and the clinical characteristics of patients with low IgM or low IgG subclass. Each of these subgroups was separately compared in two scenarios: against patients without the cognate immunodeficiency-like state and against patients without any immunodeficiency-like state (Table 4) . Patients with decreased IgM were older, presented longer disease duration, were older at SLE onset, and had lower frequency of oral ulcers than the other subgroups. Patients with low IgG 3 or low IgG 4 serum levels presented higher frequency of kidney involvement compared with the other subgroups ( Table 4) . No clinical manifestation was specifically associated with reduced IgG 2 (data not shown). All SLE patients were receiving or had received some sort of immunosuppressant therapy at the time of the study enrolment. Immunosuppressant use ( 
Discussion
Several studies have separately recorded the occurrence of individual forms of PID in SLE [1, 8, 14, 17] . This study explored the occurrence of multiple immunodeficiencylike states in a large SLE cohort using a large sample of local gender-and age-matched healthy blood donors to gauge the reference range for all immunological parameters tested. We showed that over one-fourth of patients presented evidence of humoral immunodeficiency, 4 were associated with a high frequency of kidney involvement, while low IgM was associated with low frequency of oral ulcers. There was no difference in immunosuppressant regimen between patients with and without immunodeficiency-like states. Our data confirmed some, but not all, previously reported associations of PID forms and SLE. SIgAD was present in three patients (1%), which is above the expected 0.3% in the general population. The 0.3% frequency of CGD gene carriers in this SLE cohort is notable considering the estimated 1:250 000 prevalence of this condition in the general population. Homozygous complement deficiency was not detected, but we did identify two patients with heterozygous C2 deficiency. Considering the 1:20 000 prevalence of C2 deficiency in the general population [2, 3] , the presence of 0.6% heterozygous deficiency in our cohort is noteworthy. In addition, we observed a significant skewing for low C4A gene copy number among SLE patients.
FIG. 1 Distribution of SLE and controls according to immunoglobulin serum levels
Complement deficiency has been reported to be the predominant PID form in SLE, but in the present study, there was a predominance of immunoglobulin deficiencylike states. One possible reason for this finding is that complement deficiency is much rarer than immunoglobulin deficiency. Therefore, only extremely strong associations with complement deficiency would have been detected in the analysis of 300 patients. In contrast, selective immunoglobulin deficiency is much more frequent in the general population. We hypothesize that the well-known association between complement deficiency and SLE derives from the fact that assessment of complement is part of the regular laboratory investigation of SLE patients. Therefore, every SLE patient is regularly, although unintentionally, screened for complement deficiency, while assessment of immunoglobulin levels is seldom done. Although no patient in this study presented homozygous complement component deficiency, we found a significantly higher frequency of patients with low C4A GCN in comparison with controls. Similar findings have been reported in Asian, European and North-American SLE patients [30, 31] . Individuals with low C4 GCN can display low serum C4 levels [32] , but our patients with low C4A GCN did not present low C4 serum levels and thus were not considered to have an immunodeficiency-like state.
The association between kidney involvement and low IgG 3 /IgG 4 serum levels is an original and intriguing finding. A few reports have noted association of SLE and IgG subclass deficiency [33, 34] . Jesus et al. [21] showed coexistence of IgG 2 deficiency in 5.5% of jSLE. Tamura et al. [33] reported one jSLE patient with IgG 2 and IgG 4 deficiency. An obvious concern is that the low levels of IgG subclasses observed in patients with kidney involvement might be related to urinary protein loss. However, only patients with no disease activity, and therefore no significant proteinuria, were included in the present study. One possible explanation for the association between IgG subclass deficiency-like state and LN is that a decrease in the clearance of immune complex secondary to low IgG subclass levels would favour the development of GN. This hypothesis is in line with widespread evidence of association between LN and hypomorphic polymorphism or gene deletion related to proteins relevant to immune complex clearance [35, 36] , such as C1q [37] , FcgRIIa [38] , FcgRIIb [39] and FcgRIIIb [40] .
Low IgM serum levels were associated with longer disease duration, older age at SLE onset and lower frequency of oral ulcers. An association between IgM deficiency and longer disease duration in SLE has been reported previously [4143] . This observation calls for further studies to investigate the possibility that the chronic SLE-inflammatory process could contribute to decreased IgM production. IgM is considered to play a role in the interface between innate and adaptive immune responses [42] . It is the first immunoglobulin synthesized in the fetus and in primary immune responses. IgM serum levels are stably maintained lifelong and, unlike IgG and IgA levels, appear not to be affected by conventional immunosuppressant [26] . These observations suggest that IgM plays an important and fundamental role in immunological homeostasis.
The present study confirms and extends previous observations by our group showing an overall 26% frequency of immunodeficiency-like states in jSLE, which is very close to the 28% observed in the present series of adult patients [21] . In contrast to the findings in the present study, however, complement deficiency was present in nine (two with C1q deficiency, two with C4 and five with C2) of the 19 jSLE patients with immunodeficiency-like states. The remaining 10 patients had immunoglobulin deficiency. One possible reason for the difference in the frequency of complement deficiency between adult and jSLE is that complement deficiency may represent a strong genetic influence towards SLE development, thus resulting in disease onset earlier in life. Another interesting difference observed between the two studies was the higher frequency of severe infections and higher SLICC-DI in jSLE patients with immunodeficiency-like states, which was not observed in the adult study. In fact, the mild immunodeficiency-like states observed in the adult patients are not expected to be associated with increased susceptibility to infections.
The cross-sectional design of this study does not allow determining if the observed low immunoglobulin levels represent a transient or permanent finding. In addition, even though some SLE patients from our cohort were recently diagnosed, no patient was completely free of medication at the time of study enrolment. Therefore, our data cannot rule out the possibility that the observed low IgG subclasses and IgM serum levels are secondary to immunosuppressant therapy or to the SLE immunological derangement itself. Consequently, we cannot ascribe a primary immunodeficiency label to these study subjects, and thus adopted the conservative designation immunodeficiency-like states.
Despite the above considerations, it should be appreciated that we found no clear evidence for a causal relationship between low immunoglobulin class/subclass levels and immunosuppressant or active inflammation. Recognizing that it is not feasible to study a large series of treatment-naïve SLE patients, this study was designed to minimize possible interference of immunosuppressant and inflammatory activity on the immunological parameters tested. A strong argument against the effect of immunosuppressant therapy on the observed immunological abnormalities is the fact that there was no difference in the frequency of immunodeficiency-like states between patients receiving and not receiving immunosuppressant therapy. This finding is also supported by previous studies in SLE cohorts [12, 44] and by the finding that babies delivered from SLE mothers under different www.rheumatology.oxfordjournals.org immunosuppressive regimens had normal immunoglobulin and subclasses serum levels [45] . However, the literature is controversial on this issue. Di Paolo et al. [46] showed lower IgG concentration, mainly because of subnormal levels of IgG 1 and IgG 3 subclasses, in six newborns from female kidney transplant recipients who had received ciclosporin and methylprednisolone throughout their pregnancies. A short-term of high dose of oral steroids in healthy controls has been associated with low IgG 1 , IgG 2 and IgG 3 serum levels in one study [47] , but no significant changes of IgG subclasses in another [48] . Surprisingly, these two papers showed no difference in IgG 4 serum levels, which is an apparent paradox with the recent demonstration of strong response to glucocorticoids in patients with IgG 4 -related disease [49] . Finally, a retrospective cohort showed that seven (2.4%) out of 289 MMF-treated renal transplant recipients developed chronic pulmonary infection and low IgG serum levels, suggesting that immunosuppressive therapy can be responsible for hypogammaglobulinaemia in a minority of patients [50] . Therefore, we cannot formally exclude a possible influence of immunosuppressant therapy on the altered immunoglobulin levels and prospective studies are needed to investigate this issue.
In conclusion, the current study shows that 28.7% of a cohort of 300 adult SLE patients exhibited some form of immunodeficiency-like state, with immunoglobulin deficiency being by far the most prevalent form. This finding confirms and extends our previous findings with jSLE [21] . The identification of such a large fraction of SLE patients presenting some form of underlying immunodeficiencylike state suggests the existence of a subset of SLE that may have specific pathophysiology, clinical evolution and therapeutic response. The immunodeficiency-like states observed in this series of SLE patients were not associated with increased susceptibility to or severity of infections. However, some clinical associations were observed, particularly between low IgG3/IgG4 levels and LN. Further studies are warranted to formally investigate a possible role for immunosuppressant therapy in the observed immunological alterations as well as in analysing how stable these findings are in a longitudinal temporal framework.
